Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 11, 1998, Pages 761-766

  Grif, K ^a   Dierich, M P ^a   Karch, H ^b   Allerberger, F ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; LACTATE DEHYDROGENASE; PENICILLIN G; SHIGA TOXIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANIMAL CELL; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; CELL DEATH; COLORIMETRY; CYTOSOL; ESCHERICHIA COLI O157; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VERO CELL;

EID: 0032421510     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050181     Document Type: Article

References (33)

1. O'Brien AD, LaVeck GD, Thompson MR, Formal SB: Production of Shigella dysenteriae type 1 like cytotoxin by Escherichia coli. Journal of Infectious Diseases (1982) 146:675-683
2. Strockbine NA, Marques LR, Newland JW, Smith HW, Holmes RK, O'Brien AD: Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infection and Immunity (1986) 53:135-140
3. Louise CB, Obrig TG: Shiga toxin associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infection and Immunity (1992) 60:1536-1543
4. Tarr PI: Escherichia coli O157:H7: clinical, diagnostic and epidemiological aspects of human infection. Clinical Infectious Diseases (1995) 20:9-10
5. Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin JC, Karmali MA, Krishnan C, Korn DA, Lior H: A severe outbreak of Escherichia coli O157:H7 associated hemorrhagic colitis in a nursing home. New England Journal of Medicine (1987) 317:1496-1500
6. Allerberger F, Karch H: Review of meeting: European Study Group on Enterohemorrhagic Escherichia coli. Clinical Microbiology and Infection (1997) 3:391-392
7. Ostroff SM, Kobayashi JM, Lewis JH: Infections with Escherichia coli O157:H7 in Washington state. Journal of the American Medical Association (1989) 262:355-369
8. Cimolai N, Carter JE, Morrison BL, Anderson JD: Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. Journal of Pediatrics (1990) 116:589-592
9. Cimolai N, Carter JE: Reply. Journal of Pediatrics (1990) 117:676
10. Robson WLM, Scott RB, Fick GH: Influence of antidiarrheal and antimicrobial medications on the hemorrhagic colitis associated with hemolytic-uremic syndrome. Journal of Pediatrics (1990) 117:657-676
11. Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI: Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics (1997) 100:127
12. Martin DI, MacDonald KL, White KE: The epidemiology and clinical aspects of the hemolytic-uremic syndrome in Minnesota. New England Journal of Medicine (1990) 323:1161-1167
13. Walterspiel JN, Ashkenazi S, Morrow AA, Cleary TG: Effect of subinhibitory concentrations of antibiotics on extracellular shiga-like toxin I. Infection (1992) 20:25-29
14. Bitzan M, Müller-Wiefel DE, Schwarzkopf A, Karch H: Zur Rolle von Antibiotika beim Management des Verotoxin-assoziierten hämolytisch-uremischen Syndroms. Immunität und Infektion (1992) 20:168-172
15. Yoh M, Frimpong EK, Honda T: Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunology and Medical Microbiology (1997) 19:57-64
16. Rüssmann H, Schmidt H, Heesmann J, Caprioli A, Karch H: Variants of shiga-like toxin II constitute a major component in Escherichia coli O157 strains from patients with hemolytic uremic syndrome. Journal of Medical Microbiology (1994) 40:338-343
17. Gentry MK, Dalrymple JM: Quantitative microtiter cytotoxicity assay for Shigella toxin. Journal of Clinical Microbiology (1980) 12:361-366
18. Joh K: Predictive indicators for progression to severe complications (hemolytic-uremic syndrome and encephalopathy) and their prevention in enterohemorrhagic Escherichia coli infection. Nippon Rinsho (1997) 55:700-705
19. Allerberger F, Sölder B, Caprioli A, Karch H: Enterohämorrhagische Escherichia coli und hämolytisch-urämisches Syndrom. Wiener Klinische Wochenschrift (1997) 109:669-677
20. Pavia AT, Nichols CR, Green DP, Tauxe RV, Mottice S, Greene KD, Wells JG, Siegler RL, Brewer ED, Hannon D: Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. Journal of Pediatrics (1990) 116:544-551
21. Karch H, Strockbine NA, O'Brien AD: Growth of Escherichia coli in the presence of trimethoprim-sulfamethoxazole facilitates detection of shiga-like toxin producing strains by colony blot assay. FEMS Microbiology Letters (1986) 35:141-145
22. Karch H, Gonorcy-Bermes P, Opferkuch W, Kroll HP, O'Brien AD: Subinhibitory concentrations of antibiotics modulate amount of shiga-like toxin produced by Escherichia coli. In: Adam D, Hahn H, Opferkuch W (eds): The influence of antibiotics on the host-parasite relationship II. Springer Verlag, Berlin (1995) pp. 239-245
23. Reese RE, Betts RF: Handbook of antibiotics. Little, Brown and Company, Boston (1993) pp. 79-434
24. Committee on Infectious Diseases, American Academy of Pediatrics: Report of the Committee on Infectious Diseases (Red Book). American Academy of Pediatrics, Elk Grove Village, IL (1997) p. 206
25. Wolf LE, Acheson DWK, Lincicome LL, Keusch GT: Subinhibitory concentrations of antibiotics increase the release of shiga-like toxin from Escherichia coli O157:H7 in vitro. In: Karmali MA: Proceedings of the 3rd International Symposium and Workshop on Shiga Toxin (Verotoxin)-Producing Escherichia coli Infections. VTEC'97 Committee, Baltimore (1997) p. 60
26. Spratt BG, Bowler LB, Edelman A: Membrane topology of PBPs 1B and 3 of E. coli and the production of water-soluble forms of high molecular weight PBPs. In: Shockman GD (ed): Antibiotic inhibition of bacterial cell surface assembly and function. American Society for Microbiology, Washington DC (1988) p. 292
27. Ito T, Akino E, Hiramatsu K: Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis - effect of various antibiotics on extracellular release of verotoxin. Kansenshogaku-Zasshi (1997) 71:130-135
28. Zierhut H, Semenitz E: Die Streptomycinbehandlung der Durchfallstörungen im Säuglingsalter, klinische und bakteriologische Beobachtungen. Österreichische Zeitschrift für Kinderheilkunde und Kinderfürsorge (1951) 6:196-204
29. Suarez JE, Menoza MC: Plasmid-encoded fosfomycin resistance. Antimicrobial Agents and Chemotherapy (1991) 35:791-795
30. Takeda T, Tanimura M, Yoshino K, Matsuda E, Uchida H, Ikeda N: Early use of antibiotics for STEC O157 infection reduces the risk of hemolytic uremic syndrome. In: Proceedings of the 3rd International Symposium and Workshop on Shiga Toxin (Verotoxin)-Producing Escherichia coli Infections, VTEC'97 Committee, Baltimore (1997) p. 116
31. Gemmell CG, Lorian V: Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence, and susceptibility to immunodefenses: clinical significance. In: Lorian V (ed): Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore (1996) pp. 397-452
32. Edelman R, Karmali MA, Fleming PA: Summary of the International Symposium and Workshop on Infections due to Verocytotoxin (Shiga-Like Toxin)-Producing Escherichia coli. Journal of Infectious Diseases (1988) 157:1102-1104
33. Lyte M, Arulanandam BP, Frank CD: Production of shiga-like toxins by Escherichia coli O157:H7 can be influenced by the neuroendocrine hormone norepinephrine. Journal of Laboratory and Clinical Medicine (1996) 128:392-398